Search

everythinglearnresearchcommunity

for

Search:↓

Best 2% Minox brand for mixing with pyrilutamide powder and retinoic acid sought. Advice on specific treatments discussed.

Hair loss discussion includes treatments Minoxidil, Finasteride, and RU58841. HMI 115 shows anecdotal success in Phase I trial, users seek group buy for research chemical.

The conversation discusses concerns that Anagenic's version of GT20029 might not be as effective or safe as Kintor's, with comparisons to issues faced by pyrilutamide. The chemical structure of the drug has been published.

A user is joining a clinical trial for Clascoterone, a drug approved for acne but being tested for hair loss. They previously tried finasteride with limited success and plan to share updates on their experience with the new treatment.

A user reported success with a once-a-day chewable pill containing Min 3mg, biotin 2.5mg, fin 1.1mg, vit B5 10mg, vit B6 2mg, and vit C 100mg for hair regrowth. They experienced no side effects and noticed healthier hair and more facial hair.

Injectable GHK-CU and BPC157 were discussed for hair loss, but users did not notice significant hair changes. BPC157 was noted to help with shoulder issues.

A Phase 1 update for the HMI 115 clinical trial, which involves 16 participants and is expected to end in July 2023; as well as changes to the recruitment process, including treatment protocols with Minoxidil, Finasteride, and RU58841.

A bodybuilder's hair transplant appears unnatural with a straight hairline and low density, possibly worsened by not using finasteride. The Turkish clinic is criticized for poor design, and the transplant may have been free for promotion.

The conversation is about a person rapidly losing hair and seeking information on the availability of a new treatment called scube3, as they have experienced side effects from current treatments like Minoxidil and finasteride. They are hoping scube3 will be approved soon as they believe it's their only remaining option.

The conversation is about a hair loss treatment regimen that includes finasteride, dutasteride, oral minoxidil, Dermapen, quercetin, N-acetyl L-cysteine, biotin, millet seed extract, MSM, OPC, green tea extract, high-dose vitamins B1-B12, boron, and silica. The user is seeking advice on additional treatments.

Breezula's phase 2 showed reduced efficacy after 6 months, but phase 3 had positive results, causing confusion about any changes made to the drug. There is frustration over the long timeline for hair loss treatments, with some users expressing more interest in other potential treatments like GT-20029.

Oral PTD-DBM was discussed as a potential hair loss treatment, but it was deemed ineffective in humans despite promising results in mice. The conversation concluded that trying it without VPA might be unwise.

Clascoterone is being discussed for hair loss, but its current acne formulation may not be suitable for scalp use due to potential skin irritation and lower dosage compared to Breezula. Users mention other treatments like finasteride, minoxidil, and pyrilutamide, with some expressing skepticism about clascoterone's effectiveness for hair loss.

The user is discussing their hair loss treatment stack, which includes CB-03-01, Fluridil, Alfatradiol, Cosmerna, microneedling, and Stemoxydine. They have seen some new hair growth but wish they could use finasteride.

The conversation is about hair loss treatments, specifically using finasteride, minoxidil, and biotin, with a focus on the effectiveness of Hims products. Users discuss the results, potential side effects, and the role of biotin in the treatment.

KX826 shows promise as a hair loss treatment with a 10% increase in hair count, but concerns about Kintor's marketing practices and the systemic effects of treatments like GT20029 and RU58841 remain. Users express skepticism and hope, with some preferring traditional treatments like finasteride and minoxidil.

Mallia Aesthetics has developed MAL-838, a hormone-free product derived from sCD83, which stimulates hair growth without disrupting the skin microbiome. sCD83 promotes hair growth by activating hair follicles and preventing cell death, offering a localized treatment without systemic side effects.

Discussion on hair loss treatments, focusing on Breezula, with mentions of Minoxidil, finasteride, RU58841, Pyrilutamide, GT20029, and PP405. Breezula's effectiveness is uncertain, with some trials showing minimal regrowth.

Amplifica's progress on Scube3 is unclear, with no recent updates. The conversation also mentions Minoxidil, finasteride, and RU58841 as hair loss treatments.

The conversation discusses using Bimatoprost for eyebrow regrowth and its potential use on the hairline, with concerns about cost and side effects. Alternatives like topical Minoxidil are mentioned, but the user is worried about aging and acne.

Pyrilutamide's effectiveness is questioned due to overstated claims and previous trial ineffectiveness, with some users opting for finasteride instead. Despite skepticism, some consider adding pyrilutamide to their regimen alongside treatments like bicalutamide.

The conversation discusses the delay in the PP405 Phase 2 study results, now expected by the end of 2025, and skepticism about research practices. There is also mention of optimism for Amplifica's AMP303 and a topical treatment in early testing.

Methylsulfonylmethane (MSM) is not a treatment for male pattern baldness but can accelerate hair growth and thicken miniaturized hairs, with the side effect of increased hair growth all over the body. The user asks others to share their experiences with MSM.

The conversation is about the availability of hair loss treatments Breezula, SM04554, Follica FOL-004, and Follicum FOL-005 in Canada after FDA approval, including potential delays, loopholes for obtaining them, and insurance coverage.

User is experiencing increased sebum, dandruff, and acne after taking a supplement containing biotin, iron, zinc, and calcium pantothenate along with finasteride. They are questioning if biotin is the cause and whether they should stop taking it.

A user shared progress pictures after 50 days of using a compound with 10% minoxidil, 0.1% finasteride, and biotin, expressing satisfaction with the results. Another user commented positively on the progress.

The conversation discusses the availability of Breezula, a drug for hair loss, now being sold as an acne treatment, and whether it can be applied to the scalp. Users express skepticism about new hair loss treatments and suggest waiting for FDA approval.

The conversation discusses experiences with PTD-DBM for hair loss treatment. It also mentions using Minoxidil, finasteride, and RU58841.

The post and conversation discuss KX-826 (pyrilutamide) for hair loss treatment, with positive remarks about its advertising and authenticity in China. The user changed their perspective after further research and seeing genuine advertising.

P-1075 is a more potent hair growth agent than Minoxidil, but it poses significant heart risks, making it unsafe for use. Despite promising results in macaques, concerns about its cardiotoxicity in rats have halted its development.